Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
about
PCSK9 and Atherosclerosis - Lipids and Beyond.Traditional Chinese medicine for lipid metabolism disorders.Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapyAnti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9.Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder.The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvPlasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.
P2860
Q33675963-7EFEF953-E41D-4455-BC6E-A7549A6EE68AQ33733077-DB7216D5-3A05-46D7-9B8B-BF07B8C0EB6CQ36362512-086D6430-C0EF-43DF-A59B-0F7260D732CFQ38652329-B89D74B7-F780-4193-A6A7-F2D0F9F5E8BDQ39215606-CDB9DBFD-2C6E-4F31-AD00-305152DAC79EQ40984110-EB8210EC-130E-437D-AD95-29348D8BF2FDQ41503652-62F55DBB-F764-4E8F-A453-4D8785823851Q47154672-C7DAC94F-0C47-4B45-B3B2-569B2DA80F4BQ47635484-B990FB15-1F8A-4F75-B069-B5D981DE1061Q48113239-DA4A9D0B-DC9B-4B65-9AE3-4F6B9E0D31ECQ48178320-83C6A694-3C4E-4E77-9692-8DD8A81A7128Q48209248-9492AF69-0320-4E06-9CA4-7019E225DE9EQ51737068-9CE4C301-376E-41EA-9304-568041D8F7A5
P2860
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Biology of proprotein converta ...... oprotein cholesterol lowering.
@ast
Biology of proprotein converta ...... oprotein cholesterol lowering.
@en
Biology of proprotein converta ...... oprotein cholesterol lowering.
@nl
type
label
Biology of proprotein converta ...... oprotein cholesterol lowering.
@ast
Biology of proprotein converta ...... oprotein cholesterol lowering.
@en
Biology of proprotein converta ...... oprotein cholesterol lowering.
@nl
prefLabel
Biology of proprotein converta ...... oprotein cholesterol lowering.
@ast
Biology of proprotein converta ...... oprotein cholesterol lowering.
@en
Biology of proprotein converta ...... oprotein cholesterol lowering.
@nl
P2093
P2860
P356
P1476
Biology of proprotein converta ...... oprotein cholesterol lowering.
@en
P2093
Giuseppe Danilo Norata
Hagai Tavori
Sergio Fazio
P2860
P304
P356
10.1093/CVR/CVW194
P577
2016-08-05T00:00:00Z